Longeveron (LGVN) Operating Expenses (2020 - 2026)
Longeveron (LGVN) recorded quarterly Operating Expenses of $5.0 million in Q1 2026, down 10.91% quarter-over-quarter from $5.7 million in Q4 2025, and down 7.64% on a YoY basis from $5.5 million in Q1 2025.
Longeveron (LGVN) Operating Expenses (2020 - 2026) Analysis & Trends
Longeveron's Operating Expenses history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 7.64% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $23.7 million (up 21.76% YoY), while the FY2025 annual figure was $24.1 million, up 30.88% from the prior year.
- Operating Expenses was $5.0 million for Q1 2026 at Longeveron, down from $5.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $7.4 million in Q3 2025 to a low of $3.6 million in Q1 2022.
- Historically, Operating Expenses has averaged $5.1 million across 5 years, with a median of $5.2 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses slumped 33.78% in 2024, then jumped 44.2% in 2025.
- A 5-year view of Operating Expenses shows it stood at $5.2 million in 2022, then advanced by 4.86% to $5.4 million in 2023, then fell by 11.53% to $4.8 million in 2024, then gained by 17.56% to $5.7 million in 2025, then retreated by 10.91% to $5.0 million in 2026.
- The last three Operating Expenses figures came in at $5.0 million (Q1 2026), $5.7 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -67.40 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 5.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 5.33 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | 5.22 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Sep 30, 2022 | 5.28 Mn |
| Jun 30, 2022 | 4.38 Mn |
| Mar 31, 2022 | 3.56 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Sep 30, 2021 | 5.07 Mn |
| Jun 30, 2021 | 5.27 Mn |